LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced today that its Venezuelan subsidiary LATAMEDAI VE has entered into a memorandum of understanding (MOU) with FARMASER, a pharmacy chain based in Venezuela. The collaboration aims to develop a customized artificial intelligence and automation platform designed to support FARMASER's current operations and planned expansion.
Under the MOU, the parties will collaborate on the design, adaptation, testing, and evaluation of a software platform tailored to FARMASER's operational requirements. The initial phase involves defining technical and operational specifications, adapting the software to FARMASER's pharmacy workflows, and establishing a phased development and testing process. The companies also plan to evaluate the integration of LataMed AI's CardioAI, PulmoAI, and NeuroAI models across FARMASER's three existing pharmacy locations and up to 15 planned additional locations. These AI-supported platforms are intended to assist healthcare professionals in evaluating cardiovascular, pulmonary, and neurological health information, subject to continued development, testing, regulatory requirements, and clinical protocols.
The proposed platform would also include e-commerce, prescription-management, customer-service, inventory-planning, and business-analytics functions. LataMed AI emphasized that any prescription-related or AI-supported functionality would be designed to assist administrative and healthcare workflows, not replace the professional judgment of authorized pharmacists or medical professionals. The parties are also evaluating an annual software licensing or subscription model for commercial implementation, though scope, timing, pricing, and other terms remain subject to successful development and testing, agreement on commercial terms, and definitive documentation.
Dr. Kevin Rodan Levy, CEO of LataMed AI Corp., stated, 'This memorandum of understanding represents an opportunity to apply our technology within an important part of the healthcare delivery ecosystem. Pharmacies play a central role in connecting patients with medications, healthcare products, and related services. Our objective is to work with FARMASER to develop a platform that supports its current operations and planned expansion while evaluating the integration of our AI-supported healthcare technologies across its pharmacy network.'
Management believes this collaboration aligns with LataMed AI's broader strategy of developing an integrated healthcare ecosystem connecting patients, healthcare professionals, pharmacies, insurers, payment providers, and other participants. The proposed FARMASER platform represents a potential enterprise application of the company's technology beyond its patient-facing telemedicine services, potentially adaptable to other healthcare organizations throughout Latin America. The MOU establishes a framework for cooperation but does not guarantee successful completion, commercial deployment, or revenue generation. For additional information, visit https://latamed.ai or review SEC filings at www.sec.gov.
